MacroGenics (MGNX) to Release Earnings on Thursday

MacroGenics (NASDAQ:MGNX) is anticipated to issue its quarterly earnings data after the market closes on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $34.17 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

MacroGenics Trading Down 6.0 %

Shares of MGNX stock opened at $2.05 on Wednesday. The company’s 50-day moving average price is $2.73 and its 200-day moving average price is $3.24. The stock has a market cap of $128.66 million, a price-to-earnings ratio of -1.30 and a beta of 2.12. MacroGenics has a twelve month low of $2.04 and a twelve month high of $19.54.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.